BioCentury
ARTICLE | Clinical News

Oprozomib: Preliminary Phase Ib/II data

April 8, 2013 7:00 AM UTC

Onyx reported preliminary data from an open-label, dose-escalation, U.S. Phase Ib/II trial in 32 patients with hematologic malignancies showing that a once-daily modified-release (MR) formulation of o...